Bonick Martin 4

What Happened Bonick Martin, President, CEO and a director of Ardent Health, reported receiving 195,316 shares on March 11, 2026 as an award (transaction code A). The reported acquisition price was $0.00 (total $0 reported). These shares were earned under performance-vesting restricted stock units tied to 2024 and 2025 performance and were originally granted on July 18, 2024.

Key Details

• Transaction date: 2026-03-11; Form 4 filed: 2026-03-13.
• Transaction type: A = Award/Grant; reported price: $0.00; shares acquired: 195,316.
• Footnote: Shares earned based on 2024 and 2025 performance under RSUs awarded July 18, 2024; vesting is contingent on continued service through December 31, 2026.
• Shares owned after the transaction: not disclosed in the provided filing.
• Filing timeliness: Form 4 was filed two days after the reported transaction date (appears timely under the standard 2-business-day rule).

Context This was a performance-based equity award, not an open-market purchase or sale. Awards like this are commonly used to align executive pay with company performance; because vesting is contingent on future service and performance, these shares are not immediately liquid and do not necessarily indicate immediate buying or selling intent.